FMT holds potential for treating various diseases beyond C. difficile infection, but its regulation by the FDA is crucial due to concerns about long-term effects and unintentional disease transfer.
Keep Reading
Add A Comment
Trending
- Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn’s disease: 5-year follow-up of the PROFILE trial (The Lancet Gastroenterology & Hepatology)
- Low AST and ALT Levels Are Associated with Higher Likelihood of Early-Onset Colorectal Cancer in Adults Under 45 (Epic Research)
- Helicobacter pylori exposure linked to one in five cases of bowel cancer (News Medical)
- FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer (PR Newswire)
- A robot pill the size of a large vitamin swims through a stomach on 6 water jets while a doctor steers it with a game controller, and after $21 million it still cannot be used on a patient (The Pulse)
- GLP-1 users can have ‘terrific results’ with bariatric surgery to lose additional weight (Healio)
- GI faces another round of Medicare cuts under proposed 2027 rules (GI & Hepatology News)
- Fecal Occult Blood Screening Outcomes Adjusted for Contamination Bias and Nonadherence (JAMA Network)
